Related Experiment Video
Updated: Aug 5, 2025

04:22
Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
926
Transcriptomic Analyses of Exercise Training in Alzheimer's Disease Cerebral Cortex
Michael Anekson Widjaya1, Yu-Jung Cheng2, Yu-Min Kuo3
1Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung, Taiwan.
Journal of Alzheimer'S Disease : JAD
|March 27, 2023
Summary
Exercise training impacts Alzheimer's disease (AD) mouse cortex by upregulating neuroinflammation pathways and downregulating extracellular matrix organization, offering new molecular insights into AD treatment.
Area of Science:
- Neuroscience
- Genomics
Background:
- Exercise is known to alleviate Alzheimer's disease (AD) symptoms.
- The precise molecular mechanisms, particularly in the cortex, remain unclear.
Purpose of the Study:
- To investigate molecular pathways in the AD mouse cortex affected by exercise training.
- To identify significant gene expression changes and signaling pathways influenced by exercise.
Main Methods:
- RNA-sequencing and differential gene expression analysis were performed on the cerebral cortex of 3xTg AD mice.
- Mice were divided into control (AD) and exercise training (AD-EX) groups, with swimming exercise for 1 month.
- Functional enrichment and GSOAP clustering analyses were conducted.
Main Results:
- 412 genes were significantly differentially expressed between AD and AD-EX groups.
- Upregulated genes were linked to neuroinflammation (e.g., interferon alpha beta signaling).
- Downregulated genes were associated with vascularization, memory, and extracellular matrix organization.
Conclusions:
- Exercise modulates the 3xTg mouse cortex transcriptome.
- Key changes include upregulation of interferon alpha beta signaling and downregulation of extracellular matrix organization.
- These findings provide molecular targets for AD interventions.
Related Concept Videos
Alzheimer's Disease: Treatment
233
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
233
Alzheimer's Disease: Overview
558
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
558

